Interview with Dr. Janet Woodcock new acting FDA c
Post# of 148321
An audio interview of interest to CYDY investors conducted on November 9, 2020, with the editors of New England Journal of Medicine. They discuss the EUA and Accelerated Approval processes in the scope of COVID therapeutic trials. Interesting discussion regarding the importance of trial sizes, the challenges of treating COVID across the disease stages as well as Dr Woodcocks experience with therapeutics. You can listen to this audio without subscribing to NEJM.
https://www.nejm.org/action/showMediaPlayer?d...&area=
(3)
(0)
CytoDyn Inc (CYDY) Stock Research Links